Emcure Pharmaceuticals Limited’s (IPO) opens on July 3, 2024, and closes on July 5, 2024. The allotment for the Emcure Pharmaceuticals Limited IPO is anticipated to be completed on Monday, July 8, 2024. The IPO will be listed on the NSE and BSE, with a tentative listing date set for Wednesday, July 10, 2024.
The price band for the Emcure Pharmaceuticals Limited IPO is set at Rs 960 to Rs 1008 per share. The IPO is a book-built issue of Rs 1,952.03 crores, entirely a fresh issue of 0.79 crore shares.
Emcure Pharma IPO Details
IPO Date | July 3, 2024 to July 5, 2024 |
Listing Date | [.] |
Face Value | Rs 10 per share |
Price | Rs 960 to Rs 1008 per share |
Lot Size | 14 Shares |
Total Issue Size | 19,365,346 shares (aggregating up to Rs 1,952.03 Cr) |
Fresh Issue | 7,936,507 shares (aggregating up to Rs 800.00 Cr) |
Offer for Sale | 11,428,839 shares of Rs 10 (aggregating up to Rs 1,152.03 Cr |
Employee Discount | Rs 90 per share |
Issue Type | Book Built Issue IPO |
Listing At | BSE, NSE |
Shareholding pre issue | 180,852,116 |
Shareholding post issue | 188,788,623 |
Emcure Pharma IPO Lot Size
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 14 | Rs 14,112 |
Retail (Max) | 14 | 196 | Rs 197,568 |
S-HNI (Min) | 15 | 210 | Rs 211,680 |
S-HNI (Max) | 70 | 980 | Rs 987,840 |
B-HNI (Min) | 71 | 994 | Rs 1,001,952 |
Emcure Pharmaceuticals Limited IPO Objectives
The objectives of the Issue are:
- General corporate purposes
- Repayment and/ or prepayment of all or a portion of certain outstanding
borrowings availed by the company
About Emcure Pharmaceuticals Limited Company
Emcure Pharmaceuticals, founded in 1981, is an Indian company that develops, manufactures, and markets a variety of pharmaceutical products globally.
The company has 13 manufacturing facilities in India and employs 552 scientists across five research centers. In September 2023, Emcure ranked 13th in domestic sales and led in gynecology and HIV antiviral therapies.
Domestic sales accounted for over half of its revenue, with a growth rate of 10.80% from 2019 to 2023. The company supports a robust marketing and distribution network with over 5,000 field personnel and stock lists.
Emcure Pharmaceuticals Limited Financial Information
Emcure Pharmaceuticals Limited’s revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.
Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 7,806.16 | 6,672.53 | 6,063.47 |
Revenue | 6,715.24 | 6,031.72 | 5,918.86 |
Profit After Tax | 527.58 | 561.85 | 702.56 |
Net Worth | 2,952.28 | 2,501.13 | 1,987.55 |
Reserves and Surplus | 2,722.40 | 2,293.77 | 1,791.03 |
Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
Emcure Pharma IPO Timeline
Emcure Pharma IPO opens on July 3, 2024, and closes on July 5, 2024.
IPO Open Date | Wednesday, July 3, 2024 |
IPO Close Date | Friday, July 5, 2024 |
Basis of Allotment | Monday, July 8, 2024 |
Initiation of Refunds | Tuesday, July 9, 2024 |
Credit of Shares to Demat | Tuesday, July 9, 2024 |
Listing Date | Wednesday, July 10, 2024 |
Cut-off time for UPI mandate confirmation | 5 PM on July 5, 2024 |
Conclusion
Emcure Pharmaceuticals Limited is set to launch its IPO from July 3 to July 5, 2024. With a price band of Rs 960 to Rs 1008 per share, the company aims to raise approximately Rs 1,952.03 crores through a book-built issue, consisting of both fresh issues and an offer for sale. The IPO is scheduled to be listed on both NSE and BSE, with a tentative listing date of July 10, 2024. Emcure Pharmaceuticals, established in 1981, is a leading Indian pharmaceutical company with significant market presence in gynecology and HIV antiviral therapies. The company’s revenue has shown consistent growth, though profit after tax has slightly declined in recent years. The funds from the IPO will be used for general corporate purposes and repayment of certain outstanding borrowings.